linjc16/ctgov huggingface dataset:
Right or Left for Colonoscopy?

Study Overview
=================
Brief Summary
-----------------
Colonoscopy is technically challenging. Conventionally, colonoscopy begins with patients positioned in the left lateral position. However, few published studies have explored alternatives and there is consequently little evidence to support left lateral starting position over alternatives.

Detailed Description
-----------------
We aim to perform a randomised controlled trial of right versus left lateral starting position for colonoscopy. Primary outcome: time to caecum. Secondary outcomes: patient comfort; volume of sedation used.

Official Title
-----------------
Does Right Rather Than Left Starting Position Lead to Quicker Completion of COLonoscopy?

Conditions
-----------------
Colonoscopy

Intervention / Treatment
-----------------
* Procedure: starting position in colonoscopy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: above 18 years of age, informed consent, routine or urgent procedures Exclusion Criteria: emergency colonoscopy, scheduled intubation therapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Right<br>patients will be positioned on the right-lateral position at the start of colonoscopy | Procedure: starting position in colonoscopy<br> <br> |
| Active Comparator: Left<br>patients will be positioned on the left-lateral position at the start of colonoscopy | Procedure: starting position in colonoscopy<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| time to caecum (insertion time from rectum to caecum) | insertion time from rectum to caecum | 30 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient comfort (visual analogue score) | patient comfort by visual analogue score | 5 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
patient comfort, insertion
Postoperative Analgesic Effects of Using Dexmedetomidine for Ultrasound Guided Thoracic Paravertebral Block

Study Overview
=================
Brief Summary
-----------------
we aimed postoperative analgesic effects of using bupivacaine alone or added dexmedetomidine for ultrasound guided thoracic paravertebral block in thoracotomy

Detailed Description
-----------------
paravertebral block is commonly used in the treatment for acute and chronic pain.The duration of paravertebral block could theoretically be prolonged with neurolytic agents. Dexmedetomidine ,an alfa-2 adrenoreceptor agonist, is being used and adjuvant capable of prolonging duration of sensory and motor block on nerve blocks.

Official Title
-----------------
Postoperative Analgesic Effects of Using Bupivacaine Alone or Added Dexmedetomidine for Ultrasound Guided Thoracic Paravertebral Block in Thoracotomy

Conditions
-----------------
Pain

Intervention / Treatment
-----------------
* Drug: bupivacaine
* Drug: dexmedetomidin
* Drug: serum physiologic


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ASA 1-2 18-65 aged patient undergoing thoracotomy Exclusion Criteria: chronic opioid consumption bupivacaine and dexmedetomidine allergies coagulopathy infection at the needle insertion side chronic liver and kidney disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: bupivacaine<br>0,5% 20 ml bupivacaine added 0.9% 1 ml serum physiologic on paravertebral block | Drug: bupivacaine<br>* 21 ml 0.5 %bupivacaine is applied paravertebral space<br>* Other names: marcaine;|
| Active Comparator: dexmedetomidine<br>100 mcg dexmedetomidine added to 0,5% 20 ml bupivacaine on paravertebral block | Drug: dexmedetomidin<br>* 1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space<br>* Other names: precedex;|
| Active Comparator: serum phsyologic<br>0,9% 21 ml serum physiologic | Drug: serum physiologic<br>* 21 ml serum physiologic is applied paravertebral space<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| opioid consumption | patient controlled analgesia | postoperative 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| visual analog scale | visual analog scale | postoperative 1 day |
Relationship Between PTEN and Glycemic Variability and Outcome in Critically Ill Patients

Study Overview
=================
Brief Summary
-----------------
Glycemic variability in critically ill patients is a recognized negative prognostic factor. The molecular mechanisms determining inter-patients variability in glucose metabolism during stress are not fully understood. The Phosphatase and Tensin homolog (PTEN) is known to influence glucose homeostasis by interfering in intracellular insulin signaling. Aim of this study is to ascertain whether differential expression of PTEN in critically ill patients correlates with glycemic variability and clinical outcome.

Official Title
-----------------
Influence of PTEN on Glycemic Variability and Clinical Outcome in the Critically Ill Patient.

Conditions
-----------------
Hyperglycemia, Critical Illness

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: trauma provision informed consent Exclusion Criteria: diabetes impaired fasting glucose levels

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PTEN, hyperglycemia<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of ICU stay |  | Day 1 up to day 28 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Glycemic variability as expressed by standard deviation of the glycemia measurements |  | Day 1 up to day 28 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ICU, Hyperglycemia, Length of stay
Contracture Reduction Following Bunionectomy: a Longitudinal, Controlled Trial

Study Overview
=================
Brief Summary
-----------------
To determine the efficacy of Metatarsal Dynasplint Sytem (MTP) in reducing contracture of hallux limitus secondary to Bunionectomy, in a longitudinal, controlled trial.

Official Title
-----------------
Contracture Reduction Following Bunionectomy: a Longitudinal, Controlled Trial

Conditions
-----------------
Hallux Limitus

Intervention / Treatment
-----------------
* Other: standard of care
* Device: Metarsal Dynasplint


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis 1st MTJ Contracture following Bunionectomy Exclusion Criteria: Current treatment with Botulinium Toxin-A (Botox), lower extremity Current treatment Fluoroquinolones (antibiotic medication) Current use of muscle relaxant medications Fibromyalgia Stroke, CVA, Brain Injury, Spinal Cord Injury, or any neural pathology causing plasticity or hypertonicity Treatment with electrical stimulation assisting ambulation (i.e Bioness, WalkAide, Parastep, etc.)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: control/ standard of care<br>ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Control subjects will be treated with the Standard of Care during the first 12 weeks, but after the 12 weeks patients will be fit with MTP, which delivers a low-load, prolonged-duration stretch after completion of this study. | Other: standard of care<br>* Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.<br>|
| Experimental: Dynasplint<br>ALL SUBJECTS WILL RECEIVE SHOE INSERTS AND HOME STRETCHING REGIME. Experimental subjects will be immediated treated with the Metatarsal Dynasplint, which delivers a low-load, prolonged-duration stretch for 60 minutes, three times per day. | Device: Metarsal Dynasplint<br>* Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| A Repeated Measures Analysis of Variance (ANOVA) | ANOVA will be performed to measure different in category, pain, duration to full restoration of active range of motion(AROM). | 12 months |
Galantamine in the Treatment of Post-Traumatic Headache

Study Overview
=================
Brief Summary
-----------------
Most patients with CPTH present with additional major cognitive, behavioral and somatic problems. Most drugs used currently have a negative influence on cognition. Therefore, treatment strategies addressing both the headache and cognitive disturbances in patients with CPTH are necessary. (CPTH; Chronic Post Traumatic Headache).

Detailed Description
-----------------
Headache is the most common symptom after a closed head injury, persisting for more then 2 months in 60% of the patients. CPTH is an important cause of consultations in neurology offices and headache clinics, posing a severe burden and affecting the quality of life of sufferers.

Official Title
-----------------
Galantamine in the Preventive Treatment of Chronic Post-Traumatic Headache

Conditions
-----------------
Post-Traumatic Headache, Head Trauma,Closed, Retention Disorders,Cognitive

Intervention / Treatment
-----------------
* Drug: Galantamine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age range 18-75 CPTH according to ICHD-2 Fertile woman using adequate birth control Willing and able to give informed consent Willing and able to complete the entire course of the study to comply with study instructions Stable does of preventive medication - Exclusion Criteria: Subject is pregnant or lactating Significant medical or psychiatric disease Previous failure to 4 or more adequate trials of preventive medication Patient on non-stable dose of medication used to prevent CPTH -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Galantamine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Headache Efficacy Measure; number of pain free days after 3 months |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Consumption of rescue medication |  |  | 
| Number of days with moderate or severe headache after 3 months. |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Post, Traumatic, Headache, Cognitive
Asthma Control Among Patients Receiving Inhaled Corticosteroids in Thailand

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the percentage of patients who has reached the GINA guideline of asthma treatment after receiving any inhaled corticosteroid for 3 months or longer in actual clinical practice. Such percentage for each level of severity - mild, moderate and severe persistent asthma as well as the differences of these rates will also be explored.

Official Title
-----------------
Asthma Control Among Patients Who Were Receiving Inhaled Corticosteroids in General Practice in Thailand

Conditions
-----------------
Asthma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Established persistent asthma Currently treated with any inhaled corticosteroid therapy but not SYMBICORT nor SERETIDE for 3 months or longer Exclusion Criteria: Currently participating or have participated in a study with an investigational compound within the last 30 days Current diagnosis of chronic obstructive pulmonary disease (COPD) Smoked more than 10 packs a year

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Asthma control test |  | On the survey date | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Asthma control in mild, moderate and severe persistent asthma patients |  | On the survey date | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Asthma, Inhaled corticosteroid, Thai patient eligibility, Persistent asthma
Adult ALL Treatment at Diagnosis

Study Overview
=================
Brief Summary
-----------------
The present study has been designed to give participating centers the possibility of better understanding the diagnostic and prognostic factors of ALL patients.

Official Title
-----------------
GIMEMA Guidelines for the Treatment of Adult ALL Affected Patients at Diagnosis

Conditions
-----------------
Leukemia, Lymphocytic, Acute

Intervention / Treatment
-----------------
* Drug: Vincristine
* Drug: Vincristin, Daunorubicine, Asparaginase, Methotrexate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of acute lymphoblastic leukemia (ALL) Negative myeloperoxidase stain Phenotype T (ALL-T) and B(ALL-B) Exclusion Criteria: Creatinine > 2.5mg/dL after adequate hydratation LVEF <50% Presence of documented infections not responding to antibiotic and/or antifungal therapy Presence of concomitant malignant diseases Absence of any psychological condition that does not allow to intake high doses of cortisone Patients who have received any antineoplastic chemiotherapy for more than 5 days Patients who have received any steroids for more than 10 days

Ages Eligible for Study
-----------------
Minimum Age: 14 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Vincristine|Steroids pre-treatment|
|Drug: Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
ALL, Adult
Labour Induction With Misoprostol, Dinoprostone and Bard Catheter

Study Overview
=================
Brief Summary
-----------------
This is a randomised study aimed at comparing the currently most frequently used prostaglandin dinoprostone to two other methods, the cheaper and perhaps more effective prostaglandin misoprostol and a transcervical catheter. 592 women were recruited and randomised to one of the three methods. The main outcome measures were time to delivery, rate of instrumental deliveries and maternal neonatal outcome. Our hypothesis was that misoprostol would be superior to the other methods. The main finding of our trial was that the catheter showed the shortest induction to delivery interval. There were no differences between the two other prostaglandins. No differences in maternal and neonatal outcome was found

Official Title
-----------------
A Randomised Comparison Between Intravaginal Dinoprostone Intravaginal Misoprostol and Transcervical Balloon Catheter for Labour Induction

Conditions
-----------------
Pregnancy

Intervention / Treatment
-----------------
* Drug: misoprostol
* Drug: dinoprostone
* Device: Bard Catheter (balloon catheter)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Full term singleton pregnancy with vertex presentation and with an indication for labour induction. Absence of active labour Bishop score ≤ 6. Normal CTG registration Exclusion Criteria: Previous cesarean section signs of infection immediate need for delivery any contraindication for vaginal delivery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Labour induction with misoprostol | Drug: misoprostol<br>* 0.025mg tablet vaginally every 4 hour until progress<br>* Other names: Cytotec, one quarter of a 0.100mg tablet;|
| Active Comparator: 2<br>Labour induction with dinoprostone | Drug: dinoprostone<br>* 2mg vaginal gel every 6 hours until progress<br>* Other names: Minprostin;|
| Experimental: 3<br>Labour induction with bard | Device: Bard Catheter (balloon catheter)<br>* Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated<br>* Other names: Bard Catheter;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Time from treatment start to delivery |  | At delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Labor induction, cervical ripening, misoprostol, dinoprostone, balloon catheter, prostaglandin
Causes, Analysis of the Sub-evaluating Coronary Syndromes Acute and Disparities in France in Women

Study Overview
=================
Brief Summary
-----------------
Despite efforts of learned societies, community cardiology and more generally of most players in the health, cardiovascular diseases continue to be the leading cause of death among women in France and all over the Western world, there where they fell to second place among men. Clinical practice and the disparity between the sexes are still insufficiently known. Multicenter observational study on a cross-week comparative basis with men

Detailed Description
-----------------
In France, as in other industrialized countries, ischemic heart disease is a major cause of morbidity and mortality in women. Work to improve epidemiological knowledge, prevention, screening, risk stratification and treatment of ischemic heart disease in women has a potential impact on all the issues listed. There is therefore a double challenge: A public health issue to alert the female population on cardiovascular risk and its consequences, while the female population does not feel concerned by the potential danger. A challenge for health professionals so that they have the same thing vis-à-vis the cardiovascular prevention among women and whatever their field of practice.

Official Title
-----------------
Causes, Analysis of the Sub-evaluating Coronary Syndromes Acute and Disparities in France in Women

Conditions
-----------------
Coronary Acute Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women all patients and / or men regardless of age Admitted to a cardiology department (in the intensive care unit or cardiology traditional) week of the survey, Having presented an acute coronary syndrome, regardless of the type with or without ST segment above, with or without elevated troponin, complicated or not, regardless of its support invasive or conservative, Patients who agreed to participate in the study.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Cardiology<br>The study includes all patients hospitalized for acute coronary syndrome during the week selected and who agreed to participate in the study. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clinical practices | To assess clinical practices and disparities between men and women in the management of acute coronary syndrome | 1 day |